Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Inc (NQ: PRLD )

4.000 -0.280 (-6.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prelude Therapeutics Inc

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces $25 Million Private Placement
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Pricing of Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Launch of Proposed Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid Tumors 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.